Welcome to our dedicated page for Voyager Therapeutics SEC filings (Ticker: VYGR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Voyager Therapeutics, Inc. filings document regulatory disclosures for a Nasdaq-listed biotechnology company developing neurotherapeutics for central nervous system diseases. Its Form 8-K reports include quarterly and annual financial results, corporate updates, Regulation FD investor presentations, executive officer transitions and related exhibits covering pipeline and platform information.
Proxy materials describe annual meeting matters such as director elections, advisory executive compensation votes, auditor ratification, charter matters and proposals involving authorized capital. The filing record also identifies Voyager’s common stock, par value and Nasdaq Global Select Market listing, and formalizes governance and capitalization disclosures relevant to its public-company status.
Voyager Therapeutics has a planned sale of 3,525 shares of its common stock under Rule 144. The shares have an aggregate market value of $13,552.57 and are to be sold through Fidelity Brokerage Services on NASDAQ around 02/10/2026.
The seller acquired these 3,525 common shares on 02/09/2026 through restricted stock vesting as compensation from the issuer. The filing notes that 55,600,084 shares of common stock were outstanding, providing context for the size of this transaction.
Integrated Core Strategies (US) LLC, affiliates of Millennium Management, and Israel A. Englander report significant passive ownership positions in Voyager Therapeutics, Inc. common stock. Integrated Core Strategies (US) LLC reports beneficial ownership of 3,338,862 shares, representing 6.0 % of the outstanding common stock. Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report beneficial ownership of 3,407,969 shares, or 6.1 % of the class, through entities they oversee. The filing states that the securities were not acquired and are not held for the purpose of changing or influencing control of Voyager, indicating a passive investment intent as of the event date of 01/16/2026.
Voyager Therapeutics, Inc. reported that its SVP and General Counsel, Gregory L. Shiferman, received a grant of stock options for 100,000 shares of common stock on January 6, 2026. The options have an exercise price of $4.02 per share and were issued under the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan. The options vest over four years, with one quarter of the underlying shares vesting on the one-year anniversary of the grant date and the remaining shares vesting in equal monthly installments over the following three years, contingent on his continued employment. Following this grant, he holds 100,000 stock options directly.
Voyager Therapeutics, Inc. officer Gregory L. Shiferman filed an initial ownership report on Form 3 stating that, as of 01/06/2026, he beneficially owns no securities of the company. He is identified as Senior Vice President and General Counsel, and the filing is made by a single reporting person.
Voyager Therapeutics, Inc. filed a Form 8-K to inform investors that it has posted an updated corporate investor presentation on the Investors section of its website and will distribute a letter summarizing key points from that presentation to certain stockholders. These materials are included as Exhibits 99.1 and 99.2 and are furnished, rather than filed, meaning they are not automatically subject to certain Exchange Act liabilities or incorporated into other SEC filings unless specifically referenced. The materials and related forward-looking statements discuss Voyager’s preclinical and clinical development plans, potential expansion into additional neurogenetic medicine modalities, collaboration and licensing arrangements, and the expected sufficiency of its cash resources, all subject to significant scientific, regulatory, collaboration, and funding risks outlined in the company’s risk disclosures.
Voyager Therapeutics, Inc. filed a mixed shelf registration to offer up to $400,000,000 of securities, including common and preferred stock, debt, depositary shares, subscription rights, warrants, purchase contracts, and units, in one or more offerings after this registration statement becomes effective.
The filing also includes a sales agreement prospectus for an at-the-market program of up to $100,000,000 of common stock with TD Securities (USA) LLC (TD Cowen), which is part of the $400,000,000 shelf. Proceeds, if and when raised, may be used for general corporate purposes such as R&D, advancing programs into clinical development, regulatory activities, working capital, and potential in-licenses or acquisitions. Voyager’s common stock trades on Nasdaq as VYGR. Shares outstanding were 55,600,084 as of November 3, 2025.
Voyager Therapeutics reported Q3 2025 results showing lower collaboration revenue and a wider loss as it advances its neurology pipeline. Collaboration revenue was $13.4 million versus $24.6 million a year ago, while operating expenses rose to $44.0 million from $38.4 million, driving a net loss of $27.9 million compared with $9.0 million in Q3 2024. For the first nine months, collaboration revenue was $25.0 million versus $73.7 million a year earlier, with a net loss of $92.3 million.
Cash, cash equivalents, and marketable securities totaled $229.0 million as of September 30, 2025, and management expects this to fund operations for at least 12 months. The company continues to invest in Alzheimer’s programs VY7523 (anti‑tau antibody, Phase 1 MAD started in early AD) and VY1706 (tau‑silencing gene therapy, IND planned in 2026). A subsequent event notes Novartis’ partial termination of a 2022 option and license agreement for two programs effective February 1, 2026; one Novartis program remains under that agreement.
Voyager Therapeutics, Inc. filed a Form 8-K to report that it announced its third quarter 2025 financial results and corporate updates. The company did this by issuing a press release dated November 10, 2025, which is included with the filing as Exhibit 99.1 under Item 2.02.
The press release is treated as “furnished” rather than “filed,” meaning it is not automatically subject to certain Exchange Act liabilities and will only be incorporated into other securities filings if specifically referenced. The filing also identifies Voyager’s common stock, traded on the Nasdaq Global Select Market under the symbol VYGR, and is signed by Alfred Sandrock, M.D., Ph.D., the company’s Chief Executive Officer, President, and Director.
Voyager Therapeutics, Inc. (VYGR) Chief Financial Officer Nathan D. Jorgensen reported the sale of 7,666 shares of common stock on 10/03/2025. The sales were executed under a pre-existing durable automatic sales instruction (a sell-to-cover election) tied to the vesting of restricted stock units, to satisfy tax withholding. The weighted-average price reported for the shares sold was $4.78, with individual trade prices ranging from $4.74 to $4.85. After the reported transaction, the reporting person beneficially owned 123,834 shares of common stock.
Voyager Therapeutics (VYGR) filed a Form 144 notice for a proposed sale of 5,843 common shares. The shares carry an aggregate market value of $27,936.55 and are slated for sale through Fidelity Brokerage Services LLC on or about 10/03/2025 on the NASDAQ.
The securities were acquired on 10/01/2025 via restricted stock vesting from the issuer as compensation. This is a routine compliance notice that permits the holder to sell these shares under Rule 144, subject to applicable volume and manner-of-sale conditions.